AbbVie (NYSE: ABBV) has announced its acquisition of Landos Biopharma (NASDAQ: LABP), a biopharmaceutical company specializing in autoimmune diseases. The deal includes an upfront payment of USD 137.5 million plus a potential clinical milestone payment of USD 75 million, with the transaction expected to close in the second quarter of 2024.
Through this acquisition, AbbVie will incorporate Landos Biopharma’s lead asset, NX-13, an oral NLRX1 agonist. NX-13 is currently in a Phase II proof-of-concept trial for moderate-to-severe ulcerative colitis (UC) and shows potential for use in Crohn’s disease (CD). The first-in-class drug is noted for its dual capabilities of anti-inflammatory and epithelial repair activities, making it a significant addition to AbbVie’s portfolio.- Flcube.com
